Radiation-induced B-cell lymphopenia is more than a temporary drop in a routine blood count. B cells develop through a carefully staged process that begins with hematopoietic progenitor cells in the bone marrow and continues as immature cells migrate through developmental niches before entering peripheral organs such as the spleen. Ionizing radiation can damage DNA directly and can also generate reactive oxygen species, chemically aggressive molecules that disrupt proteins, membranes and genetic material. Rapidly dividing progenitor cells are particularly vulnerable, so radiation can reduce the supply of cells needed to replenish the immune system. The spleen, meanwhile, serves as a major site for immune surveillance and B-cell organization. Its mature B cells include follicular B cells, a specialized population that participates in responses to antigens and helps coordinate antibody production. When these compartments are depleted, immune recovery depends not only on producing new cells but also on rebuilding the molecular programs that allow surviving or newly generated B cells to proliferate, mature and function.

The study’s central clue came from the behavior of histone deacetylases, or HDACs, after radiation exposure. These enzymes remove acetyl groups from histone proteins and other cellular targets, influencing how tightly DNA is packaged and which genes are accessible for transcription. Because gene expression depends partly on the physical state of chromatin, changes in HDAC activity can rapidly reshape a cell’s response to stress, inflammation and differentiation signals. The researchers found that radiation caused transcriptional dysregulation of HDACs in splenic B cells. They then tested panobinostat, a broad-spectrum or pan-HDAC inhibitor, which interferes with the activity of multiple HDAC enzymes rather than targeting only one. According to the study, panobinostat specifically counteracted the radiation-associated immune injury. The result is notable because epigenetic drugs can have wide-ranging effects: by changing patterns of gene regulation, they may influence many cellular pathways at once. In this case, the treatment appeared to favor B-cell recovery without disturbing the overall balance of T cells in the spleen.

The researchers observed benefits in both central and peripheral immune compartments. In bone marrow, panobinostat significantly restored hematopoietic progenitor cells, the early precursors from which blood and immune lineages arise. In the spleen, the drug selectively reconstituted mature B cells and the follicular B-cell compartment. This selectivity matters because a treatment that broadly stimulates cell division could potentially produce harmful imbalance or worsen inflammation. Instead, the reported pattern suggests that panobinostat enhanced the regeneration of a depleted lineage while preserving T-cell homeostasis. The study also indicates that the drug promoted in situ proliferation of mature splenic B cells after radiation. In situ proliferation means that at least part of the recovery occurred locally, through the expansion of cells already present in the spleen, rather than relying exclusively on a complete restart of B-cell development from bone-marrow progenitors. That distinction could be important after radiation, when both the source of new immune cells and the peripheral tissues that house them may be damaged.

To understand the mechanism behind the cellular recovery, the team used transcriptomic analysis, a method that measures the activity of thousands of genes across a cell population. The analysis associated panobinostat treatment with the IL-17 signaling pathway. IL-17 is best known as a cytokine family involved in communication between immune cells and tissues, particularly during inflammatory and host-defense responses. Its effects depend on intracellular adaptor and signaling proteins that transmit a receptor’s signal toward changes in gene expression. In the treated B cells, the researchers reported increased expression of key mediators including ACT1, also known as TRAF3IP2, along with TRAF5 and TRAF6. These proteins can act as molecular relay components, connecting receptor stimulation to downstream pathways that regulate inflammation, survival and transcription. The study does not establish that IL-17 signaling alone causes the regeneration, but the coordinated gene-expression changes provide a potential regulatory framework for how panobinostat may help radiation-damaged B cells resume activity.

The transcriptomic results also highlighted an interaction between B-cell identity programs and the cell’s protein-quality-control machinery. Panobinostat treatment was associated with remodeling of a chaperone network involving STIP1, DNAJA1 and HSP90. Molecular chaperones help newly produced or stress-damaged proteins fold correctly, remain stable and reach their appropriate cellular destinations. HSP90, in particular, supports a wide range of signaling proteins and transcriptional regulators, making its activity relevant to cell survival and adaptation after injury. At the same time, the drug enhanced expression of the B-cell transcription factors PAX5, EBF1 and MYC. PAX5 and EBF1 are central regulators of B-cell lineage identity and development, while MYC controls programs linked to growth, metabolism and proliferation. A coordinated increase in these factors could help surviving splenic B cells retain or recover their lineage identity while entering a regenerative state. The researchers also reported suppression of the inflammatory mediators S100A8 and S100A9, proteins commonly associated with innate immune activation and tissue stress. Together, the changes suggest that panobinostat may support regeneration by combining stronger B-cell developmental signals with reduced inflammatory pressure and improved protein management.

The findings are potentially significant because radiotherapy’s immune consequences can extend beyond the immediate treatment window. B cells influence antibody responses, antigen presentation and communication with other immune populations, so prolonged depletion may affect susceptibility to infection and the ability to mount effective immune responses. Restoring B cells without disrupting T-cell homeostasis could therefore be useful in settings where immune recovery is clinically important. Panobinostat is also an attractive candidate for investigation because it is already known as a pharmacologically active HDAC inhibitor, providing a starting point for studying dose, timing and biological effects. Yet its established activity is not synonymous with safety in this new application. HDAC inhibitors can affect gene regulation across many tissues, and the same broad action that helps injured B cells may produce unwanted effects elsewhere. The present work does not show that panobinostat protects tumors from radiation, improves cancer survival or prevents all forms of radiation toxicity. Those questions would be essential before any attempt to repurpose the drug as a radiotherapy adjunct.

The study also leaves several biological questions open. It is not yet clear which HDAC enzymes are most important in the radiation response, whether the drug acts directly on B cells or indirectly through the surrounding tissue environment, or how long the regenerated cells persist and function. Transcriptomic associations can reveal pathways that move together, but they do not by themselves prove a causal chain from HDAC inhibition to IL-17 signaling, chaperone remodeling and B-cell expansion. Future experiments will need to test individual mediators such as ACT1, TRAF5, TRAF6, HSP90, PAX5 and EBF1, potentially by selectively blocking or enhancing them. Researchers will also need to determine whether restored follicular B cells produce effective antibody responses and whether panobinostat alters the inflammatory environment in ways that influence tumor control. The work was conducted under animal-research approval at Nanchang University, and the authors acknowledge support from Chinese national and provincial funding programs. As an early, peer-reviewed accepted version, the article may still undergo editorial changes before its final version of record. Even with those limitations, the results offer a striking molecular lead: a drug that alters chromatin regulation may help the immune system rebuild after radiation by reopening the genetic programs of B-cell growth while tempering stress-associated inflammation.

At the heart of HDAC inhibitors’ assumed mode of action lies the epigenetic regulation of gene activity via modifications on histones — protein complexes around which DNA is tightly coiled inside the cell nucleus. Chemical tags like acetyl groups regulate how accessible DNA is for transcriptional machinery, thereby controlling which genes are actively expressed. HDAC enzymes remove these acetyl groups, condensing chromatin and generally repressing gene expression. Consequently, HDAC inhibitors are thought to increase histone acetylation, loosening chromatin structure and promoting the expression of genes that could suppress tumor growth or trigger cancer cell death.

Yet, this classical narrative is contradicted by emerging data suggesting that HDACs do not universally act as cancer promoters. In some cellular contexts, HDACs may function as tumor suppressors, a paradox that complicates our understanding of their biological roles. Moreover, experiments have shown that while HDAC inhibitors can augment histone acetylation levels, corresponding changes in gene expression are sometimes unexpectedly moderate, failing to align with the anticipated broad epigenetic remodeling.

The latest study, led by Dr. Zheng Sun, associate professor at Baylor and a member of the Dan L Duncan Comprehensive Cancer Center, employs an arsenal of unbiased computational bioinformatics analyses to interrogate relationships between HDAC expression levels, various cancer types, and patient outcomes. These investigations reveal a striking lack of consistent correlation; different HDAC isoforms and their abundance do not uniformly associate with cancer progression or overall survival, suggesting a far more nuanced interaction than previously appreciated.

Adding a decisive twist, the research team explored the effects of the HDAC inhibitor FK228 in mouse models of solid tumors frequently targeted in clinical trials. Surprisingly, when they genetically eliminated the ability of FK228 to inhibit its primary HDAC enzyme targets, the compound retained most of its anticancer efficacy. This dissociation between enzyme inhibition and therapeutic effect fundamentally challenges the dogma that HDAC enzymatic activities are the universal anti-cancer targets of these inhibitors.

These results provoke a paradigm shift in the field, raising the possibility that HDAC inhibitors may exert anti-cancer effects through off-target interactions with other proteins or pathways. The idea that such non-HDAC targets might mediate tumor suppression invites intensive future research to identify these alternate molecular players, which could themselves become promising drug targets, ultimately enabling more precise and effective therapies.

Understanding the multifaceted mechanism of HDAC inhibitors demands intricate chemical biology and proteomic interrogation to unveil other proteins or complexes bound or modulated by these compounds. This approach could uncover a hidden network of molecular interactions that contribute to the observed anticancer activity, illuminating new pathways of cancer vulnerability.

Beyond HDACs’ canonical role in histone deacetylation, the inhibitors may affect non-histone substrates, altering processes like protein stability, transcription factor activity, or DNA repair. Such diverse biological effects could partly explain why HDAC inhibitors exhibit varied efficacy and toxicity profiles in different cancer types and patient cohorts.

The ramifications of this study extend into the clinical domain, where HDAC inhibitors are currently employed or trialed, including hematologic malignancies and solid tumors. A refined molecular understanding will aid in patient stratification, allowing clinicians to predict who will benefit from treatment and to design combination regimens targeting complementary pathways for maximal cancer cell eradication.

Critically, this work underscores the importance of moving beyond traditional one-target drug development models toward systems-level biology approaches that consider polypharmacology as both a challenge and an opportunity in cancer therapeutics. HDAC inhibitors may serve as prototypes for a new generation of multi-targeted epigenetic modulators with tailored specificity profiles informed by molecular and phenotypic data.

Dr. Chaitra Rai, the study’s first author and a postdoctoral fellow within the Sun laboratory, emphasizes the necessity of reexamining simplistic assumptions. She highlights that relying solely on enzyme inhibition as a surrogate biomarker for drug efficacy may overlook crucial aspects of drug action, leading to suboptimal clinical outcomes and an incomplete understanding of resistance mechanisms.

Ultimately, this comprehensive investigation lays the groundwork for redefining the therapeutic landscape of HDAC inhibitors. By integrating computational modeling, molecular biology, and in vivo experimental systems, this research illuminates the complexity of cancer pharmacology and opens pathways for innovative interventions that transcend existing frameworks.

In conclusion, the discovery that HDAC enzyme activity is not the universal anticancer target of HDAC inhibitors not only reshapes fundamental scientific knowledge but also paves the way for developing next-generation epigenetic therapies. These findings compel researchers and clinicians alike to embrace a broader view of drug actions, potentially revolutionizing cancer treatment strategies in the years to come.

Subject of Research: Not applicable

Article Title: Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors.

News Publication Date: 5-Jun-2026

Web References:

• Publication DOI: 10.1038/s41392-026-02698-1
• Journal: Signal Transduction and Targeted Therapy

Keywords: Histone deacetylase, HDAC inhibitors, cancer therapeutics, epigenetics, gene expression, FK228, bioinformatics, tumor suppressors, polypharmacology, drug mechanisms, cancer biology, molecular targets